$ARNA (Arena Pharmaceuticals Inc)

$ARNA {{ '2015-08-05T21:20:10+0000' | timeago}} • Webcast

$ARNA 2Q15 Call: Believes current market valuation doesn’t really reflect the potential of pipeline or BELVIQ. ARNA is committed to improving it by advancing its pipeline through valuation inflexion points and supporting collaborators' efforts to increase patient access and use of BELVIQ.

$ARNA {{ '2017-03-14T20:45:36+0000' | timeago}} • Announcement

$ARNA's renegotiation of an agreement with Eisai is expected to provide Arena with $23MM of cash payments, including $10MM received in 4Q16, and over $80MM of potential cost relief on lorcaserin (a weight loss drug) development obligations in the next three years.

$ARNA {{ '2017-03-14T20:39:09+0000' | timeago}} • Announcement

$ARNA sees FY17 net cash used in operating and investing activities to be $80-100MM, assuming no additional partnerships and no adjustment to its development plans. Also, $ARNA hopes to report results from all three of its proprietary Phase 2 programs this year.

$ARNA {{ '2017-03-14T20:27:43+0000' | timeago}} • Announcement

$ARNA's revenue shot up 10 times to $85.3MM in 4Q16, helped by $66.1MM of revenue associated with upfront BELVIQ payments. This helped $ARNA swing to a net income of $38.3MM, or $0.16 per share, from a loss of $30.4MM, or $0.13 per share in the same quarter last year.

$ARNA {{ '2015-12-15T19:01:11+0000' | timeago}} • SEC

$ARNA's interest and other income (expense), net, was expense of $1.2MM in 3Q15, compared to income of $15.5MM in 3Q14. This change of $16.7MM was mainly due to a gain on sale of available-for-sale securities of $16.3MM realized in 3Q14 related to its sale of shares $ARNA held in TaiGen Biotechnology Co., Ltd.

$ARNA {{ '2015-12-15T18:56:01+0000' | timeago}} • SEC

$ARNA's research and development expenses fell by $2.4MM to $22.1MM in 3Q15, from $24.5MM in 3Q14. This decrease was mainly due to a decrease of $2.4MM in external clinical and preclinical study fees and internal non-commercial manufacturing costs.

$ARNA {{ '2015-11-10T22:28:51+0000' | timeago}} • Webcast

$ARNA's general and administrative expenses increased slightly to $9MM for 3Q15 compared to $8MM for same quarter of last year. G&A expenses for the last quarter included $1.8MM in non-cash share-based compensation expense, compared to $1.6MM for the third quarter of 2014.

$ARNA {{ '2015-11-10T22:27:10+0000' | timeago}} • Webcast

$ARNA's research and development expenses for 3Q15 decreased to $22.1MM from $24.5MM for 3Q14. R&D expenses for the last quarter included $2.1MM in non-cash shared based compensation expense compared to $1.8MM for the same quarter of last year.

$ARNA {{ '2015-11-10T22:24:18+0000' | timeago}} • Webcast

On the $ARNA's BELVIQ front, Ildong Pharmaceutical Co., Ltd., estimates that approx. 2.1MM tablets of BELVIQ were prescribed in South Korea in 3Q15, which equates to approx. 34,400 one-month prescriptions, representing growth in total prescriptions of approx. 18.6% compared to the previous quarter.

$ARNA {{ '2015-11-10T22:23:52+0000' | timeago}} • Webcast

On the $ARNA's BELVIQ front, IMS Health estimates that approx. 157,000 prescriptions for BELVIQ were filled in the US in 3Q15, representing growth in total prescriptions of approx. 9.8% compared to the same quarter of last year and a decrease of 14.4% compared to the previous quarter.

$ARNA {{ '2015-11-10T22:23:13+0000' | timeago}} • Webcast

During 3Q15, $ARNA's Eisai shipped approx. 106,000 60-count bottles of BELVIQ and Ildong shipped approx. 43,000 60-count bottles of BELVIQ to wholesalers. For the U.S., the gross to net discount was 53%, which reflects pay no more than $75 savings card program implemented by Eisai in January 2015.

$ARNA {{ '2015-11-10T21:52:23+0000' | timeago}} • Announcement

At 3Q15-end, $ARNA's cash and cash equivalents totaled $181.3MM and approx. 242.4MM shares of common stock were outstanding.

$ARNA {{ '2015-11-10T21:50:28+0000' | timeago}} • Announcement

During 3Q15, $ARNA announced the initiation of a Phase 1b multiple-ascending dose clinical trial of APD371, a selective and potent agonist of the cannabinoid 2 receptor.

$ARNA {{ '2015-11-10T21:49:55+0000' | timeago}} • Announcement

During 3Q15, $ARNA announced the initiation of a Phase 2 proof-of-concept clinical trial of APD334, an oral Sphingosine 1-Phosphate Subtype 1 receptor modulator for autoimmune diseases, being studied in this trial for the treatment of ulcerative colitis.

$ARNA {{ '2015-11-10T21:49:22+0000' | timeago}} • Announcement

During 3Q15, $ARNA announced plans to improve efficiencies and reduce costs as it focuses on the advancement of its R&D priorities. As part of this initiative, $ARNA reduced its US workforce by about 80 employees or 35%, which is expected to reduce annualized cash expenditures for personnel by $11MM.

$ARNA {{ '2015-11-10T21:48:22+0000' | timeago}} • Announcement

$ARNA posted a net loss of $26.4MM or $0.11 per diluted share, which compares unfavorably to a net loss of $10.67MM or $0.05 per diluted share from a year ago period. The company's revenues came in at $9.1MM, which represents an increase of 11.52% YoverY and includes $4.9MM in net product sales of BELVIQ.

$ARNA {{ '2015-09-09T14:37:28+0000' | timeago}} • SEC

As of business close on Aug. 4, 2015, there were 242,241,710 shares of $ARNA's common stock outstanding. Also, as of Aug. 4, 2015, $ARNA had outstanding a warrant to purchase 1,965,418 shares of its common stock at an exercise price of $4.34 per share that expires on Aug. 14, 2015.

$ARNA {{ '2015-09-09T14:32:25+0000' | timeago}} • SEC

G&A expenses in 2Q15 were $8.8MM, down $0.3MM or 3.3% from $9.1MM in 2Q14. The decline was mainly due to a $0.5MM decrease in patent and trademark fees. $ARNA expects G&A expenses in 2015 to be higher than that of 2014. R&D expenses in 2Q15 were $24.2MM, down $2.8MM from $27MM in the same period last year.

$ARNA {{ '2015-09-09T14:10:49+0000' | timeago}} • Announcement

$ARNA is qualified to receive payments upon regulatory approval of BELVIQ under the Teva agreement for weight loss or weight management. If BELVIQ is approved in the applicable territory, $ARNA will sell BELVIQ to Teva for a purchase price of 35% of Teva's annual net product sales.

$ARNA {{ '2015-09-09T14:10:40+0000' | timeago}} • SEC

$ARNA's revenues from its portion of Eisai net product sales of BELVIQ were $3.9MM during the quarter ended June 30, 2015. Of the $3.9MM, $3.8MM related to the sales at the Eisai product purchase price and $0.1MM related to voucher redemptions.

$ARNA {{ '2015-09-09T14:10:27+0000' | timeago}} • SEC

As of June 30, 2015, $ARNA's cash ratio was 3.5 compared to 3.28 as of June 30, 2014. Cash and cash equivalents at the end of 2Q15 were $216.7MMM compared to $200.8MM at the end of 2Q14.

Recent Transcripts

LLY (Eli Lilly and Company)
Tuesday, July 25 2017 - 1:00pm
PETS (PetMed Express, Inc.)
Monday, July 24 2017 - 12:30pm
ABT (Abbott Laboratories)
Thursday, July 20 2017 - 1:00pm
NVS (Novartis AG)
Tuesday, July 18 2017 - 12:00pm
MDT (Medtronic plc)
Thursday, May 25 2017 - 12:00pm
PTX (Pernix Therapeutics Holdings, Inc.)
Monday, May 15 2017 - 8:30pm
ARRY (Array BioPharma Inc.)
Wednesday, May 10 2017 - 1:00pm
OREX (Orexigen Therapeutics, Inc.)
Tuesday, May 9 2017 - 9:00pm
ACAD (ACADIA Pharmaceuticals Inc.)
Tuesday, May 9 2017 - 9:00pm
ARNA (Arena Pharmaceuticals Inc)
Tuesday, May 9 2017 - 8:30pm
IVC (Invacare Corporation)
Tuesday, May 9 2017 - 12:30pm
PETS (PetMed Express, Inc.)
Monday, May 8 2017 - 12:30pm
PGNX (Progenics Pharmaceuticals, Inc.)
Thursday, May 4 2017 - 12:30pm
NVO (Novo Nordisk A/S)
Thursday, May 4 2017 - 12:15pm
VVUS (VIVUS Inc.)
Wednesday, May 3 2017 - 8:30pm
AMRN (Amarin Corporation plc)
Wednesday, May 3 2017 - 12:00pm
NVO (Novo Nordisk A/S)
Wednesday, May 3 2017 - 11:00am
RIGL (Rigel Pharmaceuticals, Inc.)
Tuesday, May 2 2017 - 9:00pm
SPPI (Spectrum Pharmaceuticals, Inc.)
Tuesday, May 2 2017 - 8:30pm
MRK (Merck & Co. Inc.)
Tuesday, May 2 2017 - 12:00pm

AlphaGraphics you may like